ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26

Adicet Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$4.53−0.04 (-0.88%)

Close on Oct 19, 2026

Market cap: $48.68M
P/E (TTM): –
Dividend yield: –

Adicet Bio, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	39	59	160	258	278	89	15	9.48	37	0
Short-Term Investments	–	–	0	–	0	10	52	–	0	–
Cash & Short-Term Investments	39	59	160	258	278	99	92	9.48	37	0
Prepaid Expenses & Other	2.40	3.83	2.56	3.38	4.71	5.72	1.79	1.49	0.79	–
Other Current Assets	0.31	0.74	0.46	0.34	0.00	0.23	0.18	0.02	0.08	–
Total Current Assets	161	180	162	261	282	100	64	110	55	–
Property, Plant & Equipment	17	23	27	29	15	2.79	2.12	0.32	0.04	–
Gross Property, Plant & Equipment	44	44	42	37	21	7.65	5.76	0.41	0.04	–
Accumulated Depreciation	-27	-21	-15	-8.75	-6.33	-4.86	-3.64	-0.09	-0.01	–
Construction in Progress	–	–	–	9.30	–	–	–	–	–	–
Long-Term Investments	–	–	–	–	–	0	11	–	–	–
Operating Lease Right-of-Use Assets	11	14	17	20	20	23	1.40	–	–	–
Goodwill	–	–	0	19	19	20	–	–	–	–
Intangible Assets	–	–	–	–	0	–	–	–	–	–
Other Long-Term Assets	0.08	0.43	0.82	1.21	1.89	1.84	0.41	–	–	–
Total Assets	192	220	207	331	339	154	82	110	55	–
Accounts Payable	4.74	4.83	2.63	4.40	3.26	1.55	1.05	2.99	1.52	–
Accrued Expenses	–	–	–	–	–	–	5.48	2.73	3.99	–
Current Portion of Leases	2.84	3.13	3.22	2.49	1.57	1.22	–	–	–	–
Deferred Revenue (Current)	–	–	–	0	4.81	14	11	–	–	–
Total Current Liabilities	22	19	19	20	16	22	15	5.72	5.50	–
Long-Term Leases	11	14	18	19	19	20	–	–	–	–
Operating Lease Liabilities	14	17	21	21	21	22	1.80	–	–	–
Deferred Tax Liabilities	–	–	–	–	–	0.13	–	–	–	–
Other Long-Term Liabilities	0.06	0.12	0.13	0.11	0.12	–	0.02	0.02	–	–
Total Liabilities	33	34	37	38	36	44	28	5.74	5.50	–
Preferred Stock	0	0	0	0	0	–	–	–	–	–
Common Stock	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	774	684	551	530	471	216	9.26	176	1.85	–
Retained Earnings	-615	-498	-381	-238	-168	-106	-70	-71	-34	–
Comprehensive Income & Other	0.10	0.02	0	0	0	0.02	0.02	-0.04	–	–
Shareholders' Equity	159	187	170	292	303	110	-60	-34	-27	0
Total Equity	159	187	170	292	303	110	-60	-34	-27	0
Total Liabilities & Equity	192	220	207	331	339	154	82	110	55	–
Shares Outstanding(shares)	9.59	5.16	2.70	2.68	2.48	2.48	0.13	0.11	0.02	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -67.6%

Financial strength

Current ratio: 6.71
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 184.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.41
Dividend yield: –